In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targacept Inc.

Division of Catalyst Biosciences Inc.
www.targacept.com

Latest From Targacept Inc.

Selecta Biosciences Appoints CMO

Selecta Biosciences Inc., which is developing a novel class of targeted antigen-specific immune therapies using Synthetic Vaccine Particles (SVP), has appointed Dr Earl Sands as chief medical officer. Prior to joining Selecta, Sands was most recently chief medical officer of Targacept.

Companies

Deal Watch: Mylan Proposes $30 Billion Purchase Of Perrigo

Bristol increases R&D emphasis on gene therapy through a collaboration with Dutch biotech uniQure, paying $50 million up front with numerous potential earn-outs. Astellas becomes the third pharma to sign a “Moon Shots” partnership with MD Anderson Cancer Center.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, April 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.

BioPharmaceutical Medical Device

Deal Watch: Endo Elbows In On Valeant’s Pursuit Of Salix

Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Catalyst Biosciences Inc.
  • Senior Management
  • Mauri K Hodges, VP, Fin. & Admin., CFO
    Scott N Cullison, VP, Bus. Dev.
    Merouane Bencherif, MD, PhD, SVP & Sr. Scientific Fellow
  • Contact Info
  • Targacept Inc.
    Phone: (336) 480-2100
    100 North Main St.
    Ste. 1510
    Winston-Salem, NC 27101-4072
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register